Literature DB >> 27081907

Endovascular treatment of cerebral aneurysms using the Woven EndoBridge technique in a single center: preliminary results.

Aimee Lawson1, Tony Goddard1, Stuart Ross1, Atul Tyagi1, Kenan Deniz1, Tufail Patankar1.   

Abstract

OBJECTIVE The Woven EndoBridge (WEB) is an innovative new technique for securing cerebral aneurysms. It is designed particularly for wide-necked bifurcation aneurysms that otherwise would be difficult to treat. There is a paucity of follow-up data in the literature due to the novelty of this technique. The authors reviewed their data from cases involving patients treated at Leeds General Infirmary with the WEB device. They assessed the safety and complication risk associated with the device and clinical and radiological follow-up outcomes in their patients. This is, to their knowledge, the first publication to include the new single-layer sphere device (WEB SLS) in addition to the original dual-layer (WEB DL) and the (nonsphere) single-layer (WEB SL) devices. METHODS Data from 22 patients who underwent 25 WEB treatments were analyzed. Of the 25 WEB procedures, 3 were performed on an acute basis, 1 was performed on a semiacute basis, and the remaining 21 were elective. A novel 6-point scoring system called the Leeds WEB aneurysm occlusion scale was created to ensure accurate assessment based on the morphology of the WEB device. Outcome was assessed at follow-up by MR angiography with or without digital subtraction angiography and the modified Rankin Scale (mRS). RESULTS Deployment of the WEB device was successful in 22 (88%) of 25 procedures; 3 (12%) of the attempts at WEB treatment were abandoned. One of the patients in whom treatment was abandoned underwent a successful second attempt. Immediately after the 22 procedures with successful deployment, 4 (18%) of the patients had a complete occlusion of the aneurysm and WEB device; 10 (45%) had varying degrees of occlusion within the WEB device but no aneurysm neck or remnant; 3 (14%) had a neck remnant; and 5 (23%) had an aneurysm remnant. Of the patients with an aneurysm remnant, 1 had a complete aneurysm occlusion at ≥ 3-months follow-up. In total, 6 (27%) patients had a residual aneurysm at ≥ 3-months radiological follow-up. One of these patients was admitted with hydrocephalus secondary to a recurrent aneurysm and later received a second WEB treatment with additional coiling. Only 1 patient developed new neurological symptoms. This patient went from an mRS score of 0 to a score of 1 and had radiological evidence of a thromboembolic event. Two patients showed radiological evidence of a new thromboembolic event on follow-up MRI but were clinically asymptomatic. CONCLUSIONS The WEB has shown itself to be a promising new device with the potential to increase the scope of treatment for difficult wide-necked bifurcation aneurysms. The technique is safe, and short-term results show effective occlusion of complex aneurysms with minimal complications associated with the procedure. Long-term efficacy, however, still needs to be assessed.

Entities:  

Keywords:  ACoA = anterior communicating artery; DSA = digital subtraction angiography; ICA = internal carotid artery; ISAT = International Subarachnoid Aneurysm Trial; MCA = middle cerebral artery; MRA = MR angiography; PCoA = posterior communicating artery; SAH = subarachnoid hemorrhage; WEB; WEB = Woven EndoBridge; WEB DL = WEB dual layer; WEB SL = WEB single layer; WEB SLS = WEB single-layer sphere; Woven EndoBridge; cerebral aneurysm; interventional neuroradiology; interventional neurosurgery; mRS = modified Rankin Scale; vascular disorders

Mesh:

Year:  2016        PMID: 27081907     DOI: 10.3171/2015.4.JNS142456

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  8 in total

1.  The Woven EndoBridge (WEB) as primary treatment for unruptured intracranial aneurysms.

Authors:  Sanne Bt van Rooij; Willem Jan van Rooij; Jo P Peluso; Menno Sluzewski
Journal:  Interv Neuroradiol       Date:  2018-05-16       Impact factor: 1.610

2.  Woven Endobridge (WEB) Device as a Retreatment Strategy After Unsuccessful Surgical Clipping.

Authors:  Thomas C Booth; Carmen Parra-Farinas; Ruth-Mary deSouza; Naga Kandasamy; Jo Bhattacharya; Prem Rangi; Jonathan Downer
Journal:  World Neurosurg       Date:  2020-03-13       Impact factor: 2.104

3.  Outcome After Clipping and Coiling for Aneurysmal Subarachnoid Hemorrhage in Clinical Practice in Europe, USA, and Australia.

Authors:  Antti Lindgren; Ellie Bragan Turner; Tomas Sillekens; Atte Meretoja; Jin-Moo Lee; Thomas M Hemmen; Timo Koivisto; Mark Alberts; Robin Lemmens; Juha E Jääskeläinen; Mervyn D I Vergouwen; Gabriel J E Rinkel
Journal:  Neurosurgery       Date:  2019-05-01       Impact factor: 4.654

Review 4.  Comprehensive review of the recent advances in devices for endovascular treatment of complex brain aneurysms.

Authors:  Kavi Fatania; Dr Tufail Patankar
Journal:  Br J Radiol       Date:  2021-10-05       Impact factor: 3.039

5.  Woven Endobridge (WEB) augmented by Y-stent in a shallow basilar tip aneurysm.

Authors:  Nathan J Nordmann; Matthew W Weber; Hayan Dayoub
Journal:  J Cerebrovasc Endovasc Neurosurg       Date:  2022-02-17

Review 6.  Innovation in neurosurgery: less than IDEAL? A systematic review.

Authors:  I S Muskens; S J H Diederen; J T Senders; A H Zamanipoor Najafabadi; W R van Furth; A M May; T R Smith; A L Bredenoord; M L D Broekman
Journal:  Acta Neurochir (Wien)       Date:  2017-08-06       Impact factor: 2.216

7.  What is the hemodynamic effect of the Woven EndoBridge? An in vivo quantification using time-density curve analysis.

Authors:  Philipp Gölitz; Hannes Luecking; Philip Hoelter; Frauke Knossalla; Arnd Doerfler
Journal:  Neuroradiology       Date:  2020-03-13       Impact factor: 2.804

8.  Endovascular treatment of wide-necked intracranial aneurysms using the novel Contour Neurovascular System: a single-center safety and feasibility study.

Authors:  Christopher Yusuf Akhunbay-Fudge; Kenan Deniz; Atul Kumar Tyagi; Tufail Patankar
Journal:  J Neurointerv Surg       Date:  2020-01-22       Impact factor: 5.836

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.